A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Carboplatin; Docetaxel; Doxorubicin; Gemcitabine; Liposomal doxorubicin; Paclitaxel

Criteria

Inclusion Criteria:

• Documentation of an advanced solid tumor

• No more than 2 previous anticancer therapies

• good performance status

• adequate bone marrow, liver, and renal function / adequate blood test values

• willing to use birth control measures

Exclusion Criteria:

• No residual toxicities resulting from previous therapy

• no known allergies, hypersensitivity, or intolerance to antibodies or chemotherapies

• clinically significant bleeding or requiring concurrent therapeutic dose of anticoagulation